Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy-Reference-Cited by-同舟云学术

Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy

Published:2015-10-21 Issue:310 Volume:7 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Li Rui¹,Rezk Ayman¹,Miyazaki Yusei¹,Hilgenberg Ellen²,Touil Hanane¹,Shen Ping²,Moore Craig S.¹,Michel Laure³,Althekair Faisal¹,Rajasekharan Sathy¹,Gommerman Jennifer L.⁴,Prat Alexandre³,Fillatreau Simon²,Bar-Or Amit¹⁵,

Affiliation:

1. Neuroimmunology Unit, Montreal Neurological Institute, McGill University, 3801 University Street, Montreal, Quebec H3A 2B4, Canada.

2. Deutsches Rheuma-Forschungszentrum, a Leibniz Institute, Charitéplatz 1, 10117 Berlin, Germany.

3. Centre de Recherche du CHUM (CRCHUM) and Department of Neuroscience, Université de Montréal, 900 Saint Denis Street, Montreal, Quebec H2X 0A9, Canada.

4. Department of Immunology, Medical Sciences Building, University of Toronto, Toronto, Ontario M5S 1A8, Canada.

5. Experimental Therapeutics Program, Montreal Neurological Institute, McGill University, 3801 University Street, Montreal, Quebec H3A 2B4, Canada.

Abstract

GM-CSF–producing B cells contribute to multiple sclerosis pathogenesis and the therapeutic action of B cell depletion.

Funder

Research Foundation of the MS Society of Canada

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference33 articles.

1. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura